Paolo A. Ascierto

机构：Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", University of Naples Federico II · ORCID：0000-0002-8322-475X

发表论文 1684 篇 · 总被引 112417 次 · h-index 128

代表论文

• MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition (2026 · Clinical Cancer Research · 被引 1)
• IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanoma (2026 · Annals of Oncology · 被引 1)
• COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600–Mutant Advanced Melanoma (2026 · Journal of Clinical Oncology)
• Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial (2026 · Journal of Clinical Oncology)
• Circulating thymidine kinase activity predicts survival and optimal treatment sequencing in BRAF-mutated metastatic melanoma in the SECOMBIT trial (2026 · Clinical Cancer Research)
• Tables S1-S10 from MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition (2026)